Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder in 2011
and mammalian target of rapamycin (mTOR
InChi: InChI=1S/C13H15N5
cell-permeable and selective spastin (a microtubule-severing AAA (ATPases associated with diverse cellular activities) protein) inhibitor with IC50 of 99 nM for Human spastin
7-Chlorokynurenic acid sodium salt Size:Contact [email protected] for quotation Vilazodone was approved by the7 Chlorokynurenic acid sodium salt (7 CKA sodium salt) is a potent and selective antagonist of the glycine B coagonist site of the N methyl D aspartate (NMDA) receptor (IC50=0. 56 M). 7 Chlorokynurenic acid sodium salt is also a potent inhibitor of the reuptake of glutamate into synaptic vesicles with a Ki of 0. 59 M. 7 Chlorokynurenic acid sodium salt has potent antinociceptive actions after neuraxial delivery. Product information CAS Number: 1263094
US$ 110.00
US$ 54.00
US$ 36.00
US$ 90.00
US$ 89.99
US$ 60.00
US$ 40.00
US$ 60.00
US$ 138.00
US$ 60.00
US$ 60.00
US$ 150.00
US$ 55.00
US$ 83.00
US$ 200.00